The study evaluated the in vitro activity of ceftolozane-tazobactam (C/T) against 94 unique 29 clinical isolates of Enterobacter cloacae complex (ECC). No difference was observed 30 according to the ECC cluster. The in vitro activity greatly varied depending on the β-31 lactamase-producing profile: 100%, 67% and 19% of wild-type, ESBL-producing, and AmpC-32 overproducing strains were susceptible to C/T, respectively. The use of C/T could be of 33 interest for the treatment of some infections caused by ESBL-producing AmpC-non-34 overexpressing ECC isolates.
4
The species belonging to the Enterobacter genus are responsible for 5-10% of infections 36 among patients hospitalized in intensive care units (ICUs) and primarily due to the members 37 of the Enterobacter cloacae complex (ECC) (1, 2) . Actually, ECC is composed of 13 clusters 38 among which three (C-III, VI and VIII) are the most frequently recovered from human clinical 39 specimens (3,4). All ECC members intrinsically harbour a chromosomal ampC gene coding for 40 a cephalosporinase (2,5-7). Among these third generation cephalosporin (TGC)-resistant 41 isolates, approximately one third has acquired plasmid-mediated extended-spectrum β-42 lactamases (ESBLs) while the remaining two thirds express a high-level production of 43 cephalosporinase (HL-CASE) caused by ampC derepression that results from chromosomal 44 mutations (6).
45
Ceftolozane-tazobactam (C/T) is a novel TGC combined with a classical inhibitor of β-46 lactamase (ratio of 2:1), which has recently been approved for the treatment of complicated 47 intra-abdominal and urinary tract infections (8). Although ceftolozane has been developed to 48 be more stable than other TGCs against natural AmpC produced by P. aeruginosa (9), much 49 less is known about its activity against other intrinsically AmpC-producing species, such as 50 ECC. Indeed, previous studies have mainly described the in vitro activity of C/T against 51 Enterobacter spp. with no distinction of species and/or phenotypes of resistance (10-13). In 52 addition, no data is available about the in vitro activity of C/T according to the ECC cluster.
53
The purpose of the study was then to 1) evaluate the in vitro activity of C/T against a Caen were included in the study (3). Note that the strains were identified by MALDI-TOF 61 mass spectrometry (Microflex LT; Bruker Daltonics, Bremen, Germany) and ECC members 62 were clustered by hsp60 sequencing as previously described (7). MICs of C/T (C provided by (Table S1 ). Total RNAs were 75 extracted as previously described (7). Transcript levels were determined by the DeltaDelta Ct 76 method using the rpoB gene as housekeeping control gene (Table S1) , and the fold change 77 (FC) of expression was calculated between TGC-resistant strains and WT strains of the same 78 cluster. HL-CASE was defined if the FC was higher than 2. ESBLs were characterized as 79 previously described (14-16). Twelve of the 13 clusters were represented in the study (Table S2) . Among them, C-III (21%, 82 20/94), C-VI (20%, 19/94) and C-VIII (28%, 26/94) were predominant, as previously described 83 (Table S2 ) (4). Note that none of the studied clusters expressing a WT phenotype exhibited 84 an intrinsic resistance to the C/T in spite of the genetic variability of the ampC gene (7).
85
Among the 94 isolates, four antimicrobial susceptibility phenotypes were distinguished: WT 86 34% (32/94), ESBL alone 10% (9/94), ESBL+HL-CASE 20% (19/94) and HL-CASE 36% (34/94) 87 (Tables 1 and S2) . By using the disk method with or without cloxacillin (250 mg/L), the HL-88 CASE phenotype was not highlighted in 21% of isolates (4/19) presenting an ESBL+HL-CASE 89 combined phenotype. By contrast, the expression of ampC allowed to accurately 90 discriminate between all ESBL and ESBL+HL-CASE phenotypes (P <0.0001) (Figure 1) . Among 91 the 28 isolates expressing an ESBL phenotype (ESBL alone and ESBL+HL-CASE), four genes 92 encoding such β-lactamases were identified: bla CTX-M-15 (17/28, 61%), bla SHV-12 (9/28, 32%), 93 bla CTX-M-9 (2/28, 7%) and bla TEM-15 (1/28, 4%). Note that one isolate co-produced bla CTX-M-15 94 and bla SHV-12 genes ( Table S3 ). The distribution of ESBLs was similar to that recently 95 described in French E. cloacae isolates (CTX-M-15, 52%; SHV-12, 38%; CTX-M-9, 10%) (17).
96
Besides ESBL production, plasmid-mediated AmpC β-lactamase genes were also identified in 97 two isolates (bla CMY-4 and bla DHA-1 ) and one strain harboured the acquired OXA-48-like 98 carbapenemase OXA-204 (Table S3 ). 99 For the 32 isolates with a WT phenotype, all were categorized as susceptible for all tested β-100 lactams except one strain that was not susceptible to CAZ (MIC = 2 mg/L) according to 101 EUCAST breakpoints ( Table 1) . MICs of C/T ranged from 0.12 to 0.5 mg/L with MIC 50 and 102 MIC 90 at 0.25 and 0.5 mg/L, respectively ( Table 1) ESBL, E te ded-spe tru β-la ta ase; HL-CASE, High-level produ tio of ephalospori ase.
